Ensign Peak Advisors
BOLT icon

Ensign Peak Advisors’s Bolt Biotherapeutics BOLT Stock Holding History

Ensign Peak Advisors’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-925
Closed -$51K – 2169
2022
Q1 		$51K Hold
925
– – ﹤0.01% 2127
2021
Q4 		$91K Sell
925
-520
-36% -$98.7K ﹤0.01% 2076
2021
Q3 		$366K Buy
1,445
+945
+189% +$267K ﹤0.01% 1681
2021
Q2 		$155K Hold
500
– – ﹤0.01% 1746
2021
Q1 		$329K Buy
+500
New +$325K ﹤0.01% 1666

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Ensign Peak Advisors's BOLT Position: Q2 2022 in Review

Ensign Peak Advisors sold out of Bolt Biotherapeutics (BOLT) in Q2 2022, closing a stake of 925 shares — an estimated $51K sold.

Ensign Peak Advisors first reported a position in BOLT in Q1 2021 and held it in 5 quarters. The position peaked at $366K in Q3 2021. 61 funds tracked by Wall St. Rank hold BOLT as of Q2 2022.

  • Ensign Peak Advisors reported no remaining Bolt Biotherapeutics position as of Q2 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 925 Bolt Biotherapeutics shares in Q2 2022, an estimated $51K.
  • Ensign Peak Advisors first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 5 quarters.
  • Ensign Peak Advisors's Bolt Biotherapeutics position peaked at $366K in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.